Previously recorded as Quiapeg AB (to 2015)
11 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2031. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Dec 2031
Next term end
5
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jun 2033 · High confidence
Also notable
Ends Dec 2031 · Low confidence
Also notable
Ends Jun 2033 · High confidence
Also notable
Ends Mar 2038 · High confidence
Also notable
Ends Mar 2038 · High confidence
Conjugates of Tumor Necrosis Factor Inhibitors to Functionalized Polymers
US 9,220,789
The most cited patent in this portfolio, cited by 34 later US patents, top 25% of utility patents granted in 2015 in our data. Protection runs to 2033.
Functionalized Polymers
US 10,125,220
Cited by 18 later US patents, top 25% of utility patents granted in 2018 in our data. Protection runs to 2031.
Conjugates of Biologically Active Molecules to Functionalized Polymers
US 10,383,946
Cited by 10 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2033.
Releasable Conjugates
US 11,786,599
Cited by 6 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2038. A terminal disclaimer caps this term to an earlier patent's.
Releasable GLP-1 Conjugates
US 11,357,828
Granted 2022. Computed term ends 2038. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 15 to 20, 2027 · next Feb 15
- 2 fees due Apr 3 to 17, 2027 · next Apr 3
- 1 fee due Jun 29, 2027The maintenance fee for Conjugates of Tumor Necrosis Factor Inhibitors to Functionalized Polymers (US 9,220,789) comes due Jun 29, 2027. Unpaid by Dec 29, 2027, it lapses early.
- 1 fee due Oct 16, 2027The maintenance fee for Releasable GLP-1 Conjugates (US 11,957,735) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 21, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Conjugates of Tumor Necrosis Factor Inhibitors to Functionalized Polymers | 4 in force | to Jun 2033 |
| Releasable GLP-1 Conjugates | 2 in force | to Mar 2038 |
| Conjugates of Biologically Active Molecules to Functionalized Polymers | 2 in force | to Jun 2033 |
| Functionalized Polymers | 2 in force | to Jan 2033 |
| Releasable Conjugates | 1 in force | to Mar 2038 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,125,220 | Functionalized Polymers Grace period ended · Low confidence | Grace period ended | Low confidence | |
| US 11,773,219 | Functionalized Polymers In force · High confidence | In force | High confidence | |
| US 9,220,789 | Conjugates of Tumor Necrosis Factor Inhibitors to Functionalized Polymers In force · High confidence | In force | High confidence | |
| US 10,207,007 | Conjugates of Tumor Necrosis Factor Inhibitors to Functionalized Polymers In force · High confidence | In force | High confidence | |
| US 10,383,946 | Conjugates of Biologically Active Molecules to Functionalized Polymers In force · High confidence | In force | High confidence | |
| US 10,653,788 | Conjugates of Tumor Necrosis Factor Inhibitors to Functionalized Polymers In force · High confidence | In force | High confidence | |
| US 11,510,989 | Conjugates of Biologically Active Molecules to Functionalized Polymers In force · High confidence | In force | High confidence | |
| US 11,723,981 | Conjugates of Tumor Necrosis Factor Inhibitors to Functionalized Polymers In force · High confidence | In force | High confidence | |
| US 11,357,828 | Releasable GLP-1 Conjugates In force · High confidence | In force | High confidence | |
| US 11,786,599 | Releasable Conjugates In force · High confidence | In force | High confidence |
Also on record, not counted in the 11: 8 patents ended · 2 applications pending · 3 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.